Announcements Trials

Browse Landscape

Phase

Phase NA 5 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 249 Carcinoma, Non-Small-Cell Lung 224 Prostatic Neoplasms 114 Neoplasms 105 Multiple Myeloma 90 Neoplasm Metastasis 74 Colorectal Neoplasms 73 Parkinson Disease 4, Autosomal Dominant Lewy Body 69 Lung Neoplasms 64 Ovarian Neoplasms 61 Leukemia, Myeloid, Acute 50 Melanoma 47 Carcinoma, Hepatocellular 47 Carcinoma, Renal Cell 45 Leukemia, Lymphocytic, Chronic, B-Cell 44 Triple Negative Breast Neoplasms 42 Urinary Bladder Neoplasms 41 Stomach Neoplasms 41 Squamous Cell Carcinoma of Head and Neck 41 Recurrence 40 Brain Neoplasms 39 Myasthenia Gravis 37 Small Cell Lung Carcinoma 34 Nasopharyngeal Carcinoma 34 Lymphoma, Follicular 34 Head and Neck Neoplasms 34 Rectal Neoplasms 31 Pancreatic Neoplasms 31 Lymphoma, Large B-Cell, Diffuse 30 Endometrial Neoplasms 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Polyps × 1 year × Clear all

NCT06950385 2026-05-22

SERENTA

Rapamycin Holdings Inc.

Phase 3 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Polyps

Data powered by HemOnc (CC BY 4.0) Colophon ⚡